Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HA-irinotecan
- Development stage
- Phase 3
- Lead developer
- Australian
- Modality
- Small Molecules, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous
01
Overview
HA-irinotecan is a targeted formulation of the cytotoxic agent irinotecan, developed using Alchemia's HyACT (Hyaluronic Acid Chemotherapy Targeting) platform. The drug consists of irinotecan non-covalently formulated with hyaluronic acid (HA), a naturally occurring polymer that binds to the CD44 receptor. Since CD44 is frequently overexpressed in various solid tumors, including colorectal cancer, the HA component is designed to selectively deliver irinotecan to the tumor site, potentially enhancing efficacy and reducing systemic side effects. In a pivotal Phase 3 trial (COL-003) for metastatic colorectal cancer, HA-irinotecan failed to demonstrate a statistically significant improvement in progression-free survival compared to standard irinotecan, leading to the discontinuation of its primary development program by Alchemia and its subsequent acquisition by Panther Biotechnology.
- Brand names
- HyACT
- Other names
- hyaluronan-irinotecanHyACT-Irinotecan
02
Targets
CD44 (CD44 antigen)TOP1 (DNA Topoisomerase I)
Beyond the preview
Go deeper on HA-irinotecan.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on HA-irinotecan.